SCHEMBL7535819

SCHEMBL7535819

COc1ccc(Sc2c(F)c(Cl)c(F)c(Cl)c2F)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB1 Q9H4B7 4/20 0.41
RAB9A P51151 2/20 0.38
LMNA P02545 2/20 0.38
HTT P42858 2/20 0.38
MAPK1 P28482 1/20 0.38
KDM1A O60341 2/20 0.36
ALDH1A1 P00352 2/20 0.35
MEN1 O00255 1/20 0.35
NPC1 O15118 1/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
AR P10275 2/20 0.35
PTGS2 P35354 2/20 0.33
KCNQ3 O43525 1/20 0.33
KCNQ2 O43526 1/20 0.33
TUBB4A P04350 1/20 0.33
TUBB P07437 1/20 0.33
TUBA3C P0DPH7 1/20 0.33
TUBA1B P68363 1/20 0.33
TUBA4A P68366 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7535563 0.87 TUBB1 (0.45) TUBB1RAB9ALMNAHTTMAPK1
SCHEMBL7534283 0.75 TYMS (0.42) LMNAALDH1A1ARPTGS1
SCHEMBL18680826 0.74 RAB9A (0.46) TUBB1RAB9ALMNAHTTMAPK1
SCHEMBL2894292 0.72 LMNA (0.47) TUBB1RAB9ALMNAHTTMAPK1
SCHEMBL7533149 0.71 TUBB1 (0.45) TUBB1LMNAALDH1A1MEN1KMT2A
SCHEMBL23183246 0.71 RAB9A (0.46) TUBB1RAB9ALMNAHTTMAPK1
SCHEMBL18680665 0.69 RAB9A (0.44) TUBB1RAB9ALMNAHTTMAPK1
SCHEMBL1765256 0.68 LMNA (0.50) TUBB1RAB9ALMNAHTTMAPK1
SCHEMBL7535447 0.67 KMT2A (0.48) TUBB1LMNAHTTMAPK1ALDH1A1
SCHEMBL1023561 0.66 LMNA (0.48) TUBB1RAB9ALMNAHTTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 TUBB1 446/4885RAB9A 3562/4885LMNA 2006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.